# SPARC-1 (NCT04028245)

> A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: spartalizumab plus canakinumab
- Indication: localized clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04028245
- Phase: EARLY_PHASE1
- Status: COMPLETED
- Sponsor: Columbia University
- Conditions: Carcinoma, Renal Cell
- Interventions: Spartalizumab; Canakinumab
- Enrollment: 17
- Primary outcome: Percentage of subjects who proceed to radical nephrectomy

## Indexed commentary on SPARC-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=sparc-1-nct04028245